UPCC 10519 / I5B-MC-Y001: An Open-Label Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
Enrolling By Invitation
99 years or below
All
2 participants needed
1 Location
Brief description of study
The purpose of this program is to allow patients who, in consultation with their treating physician, feel it is in their best interest to continue to receive olaratumab. Only patients with soft tissue sarcoma who are already being treated with olaratumab may enter this program.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: oncology, sarcoma
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 834053
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
